Diabetes Mellitus a Chronic Heart Failure;Diabetes Mellitus a Chronické Srdeční Selhání

Vnitrni Lekarstvi

Volumn 49, Issue 12, 2003, Pages 927-934

  Špinar, Jindřich ^a   Vitovec J ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Diabetes mellitus; Heart failure; Hypertension; Ischemic heart disease; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL;

ARTICLE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RISK FACTOR;

EID: 1642518578     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. American Diabetes Association: Diabetic Nephropathy. Diabetes Care 2002; 25 (Supp. 1): 85-89
2. Bartnik M., Malmberg K., Ryden L.: Managing heart disease. Diabetes and the heart: compromised myocardial function - a common challenge. Eur. Heart J. 2003; 5: B33-B41
3. Becker, A., Bos, G., de Vegt, F. et al.: Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. Europ. Heart J. 2003; 24: 1406-1413
4. Berková, M.: Sledování diastolického plnění levé komory srdeční u diabetik̊u 1. typu a srovnání diastolicky̌ch ukazatelů s ukazateli kardiální autonomní neuropatie. Kandidátská disertační práce. Olomouc 2003: s. 108
5. Cleland, J. G. F., McGowan, J., Clark, A.: The evidence for betablockers in heart failure. Brit. Med. J. 1999; 318: 824-825
6. Cleland, J. G. F., Cohen-Solal, A., Aguilar, J. C. et al.: Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme) - an international survey. Lancet 2002; 360: 1631-1641
7. Cohen-Solal, A.: Diastolic heart failure: myth or reality. Eur. J. Heart Failure 2002; 4: 401-402
8. Corr, L. A., Stables, R.: Managing heart disease. Coronary revascularisation: knife or catheter? Eur. Heart J. 2003; 5: B43-B48
9. Dahlof, B., Devereux, R. B., Kjeldsen, S. E. for the LIFE investigators: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
10. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes. Lancet 2001; 357: 905-910
11. Dickstein, K., Kjekshus, J. and OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-760
12. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur. Heart J. 2001; 22: 554-572
13. Fibrinolytic Therapy Trialist Collaborative Study Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction. Collaborative overview of early mortality and major morbidity results from all randomised trials. Lancet 1994; 343: 311-322
14. Hardin, N.: The myocardial and vascular pathology of diabetic cardiomyopathy. Coron. Artery Disease 1996; 7: 99-108
15. Hasdai, D., Granger, Ch. B., Srivatsa, S. S. et al.: Diabetes mellitus and Outcome after Primary Coronary Angioplasty for Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2000; 35: 1502-1512
16. Horky̌, K., Widimsky̌, J. sen., Cífková, R. et al.: Doporučení diagnosticky̌ch a léč ebných postupů u arteriální hypertenze - verze 2000. Vnitř. Lék. 2000_ 46 (suppl. 1): 5-13
17. Charvát, J., Hlaváček, K., Vaněček, T. et al.: Výsledky koronarografických nálezů a prognóza nemocných s diabetes mellitus a ischemickou chorobou srdeční. Cor vasa 2001; 43 (10): 483-487
18. Chlumský, J.: Vliv kompenzace diabetu na diastolické plnění levé komory. Vnitř. Lék. 1994; 40 (2): 93-95
19. Chobanian, A. V.: JNC 7 Express. NIH publication 2003; 03-5233: 1-52
20. Kanel, W. B., McGee, D. L.: Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 1979; 2: 920-926
21. MERIT HF study group: Effect of metoprolol CR/XL in chronic hear failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 1999; 353: 2000-2007
22. Niles, N. V., McGrath, P. D., Malenka, D. et al.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularisation. Results from a large regional prospective study. J. Am. Coll. Cardiol. 2001; 37: 1008-1015
23. Norhammar, A., Malmberg, K.: Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome. Eur. Heart J. 2000; 21: 1293-1294
24. Kanel, W. B., Hjortland, M., Castelli, W. P.: Role of diabetes in congestive heart failure: The Framingham Study. Am. J. Cardiol. 1974; 34: 29-34
25. Olšovský, J.: Diabetes mellitus a hypertenze. In: Spinar, J. Vítovec, J., Zicha, J.: Hypertenze - diagnostika a léčba. Grada 1999; 1: 228 s.
26. Packer, M., Poole-Wilson, P. A., Armstrong, P. W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318
27. Perušičová, J.: Diabetické makroangiopatie a mikroangiopatie. Galen 2003, 262 s.
28. Remme, J. W., Swedberg, K.: Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 2001; 22: 1527-1560
29. Rubins, H. B., Robins, S. J., Collins, D. et al. for the VA-HIT group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N. Engl. J. Med. 1999; 341: 410-418
30. Rubler, S., Dlugash, J., Yuceoglu, Y. et al.: New type of cardiomyopathy associated wit diabetic glomerulosclerosis. Am. J. Cardiol. 1972; 30: 595-602
31. Rydén, L., Armstrong, W. P., Cleland, J. G. F. et al.: Efficacy and safety of high dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Eur. Heart J. 2000; 21: 1967-1978
32. Shehadeh, A., Regan, T. J.: Cardiac consequences of diabetes mellitus. Clin. Cardiol. 1995; 18: 301-305
33. Stratton, I. M., Adler, A. I., Neil, H. A. et al.: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observentional study. BMJ 2000; 321: 405-412
34. Suskin, N., McKelvie, R. S., Burns, R. J.: Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur. Heart J. 2000; 21: 1368-1375
35. Swan, J. W., Walton, C., Godsland, I. et al.: Insulin resistance in chronic heart failure. Eur. Heart J. 1994; 15: 1528-1532
36. Špinar, J., Vitovec, J.: Přehled nejvýznamně jších studií u hypertenze a diabetes mellitus. Vnitř. Lék. 1999; 45 (11): 677-679
37. Špinar, J., Vítovec, J., Kubecová, L. et al.: Klinické studie v kardiologii. Grada 2001: 485 s.
38. Špinar, J., Vítovec, J.: Hypertenze a diabetes mellitus. Causa subita 2001; 4 (5): 208-209
39. Špinar, J., Hradec, J., Málek, I. et al.: Doporučení Doporudeni pro diagnostiku a léčbu chronického srdečního selhání. Cor et vasa 2001; 6 (43): K123-K138
40. Špinar, J., Musil, V., Pozdíšek, Z. et al.: Profil pacienta propuštěněho z interního oddělení v roce 2002. Staré splavy, Echodny 2003
41. Špinar, J., Vitovee, J., Fričová, K. et al.: Použití ACE inhibitorů a statinů v ambulanci praktického lékaře, internisty a kardiologa. Kardiologická revue 2003; 3: 113-119
42. Špinarová, L., Toman, J., Meluzín, J. et al.: Diabetes mellitus u chronického srdečního selhání. Cor et Vasa 2003: 45(4S): 96
43. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
44. The CAPP investigators: CAPPP: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial. Lancet 1999; 353: 611-616
45. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe, Part 1: patients characteristics and diagnosis. Eur. Heart J. 2003; 24 (5): 442-463
46. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe, Part 2: treatment. Eur. Heart J. 2003; 24 (5): 464-474
47. The UKPDS investigators: UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes. Lancet 1998; 352: 837-865
48. The CHARM investigators: CHARM ESC Viena 2003; ústní sdělení
49. Yususf, S., Gerstein, H., Hoogwerf, B. et al.: The HOPE study. JAMA 2001; 286: 1882-1885
50. Zanchetti, A. for the guidelines committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011-1023